Tralokinumab

A4DAB276 | Immune-mediated / inflammatory disorders | Approved

Target IL13

Isotype / Subclass G4 / IgG4

Company

Cambridge Antibody Technology Icahn School of Medicine at Mount Sinai LEO Pharma MedImmune

Clinical Status Approved

Format Whole mAb

Synonyms

CAT-354 CAT354 CAT 354 Adbry Adtralza LP 016 LP016 LP-016 LP-16 LP16 LP 16

pH Formulation 5.5

IMGT PubChem (135339998) PubChem (160687963) PubChem (249565681) PubChem (347911293) PubChem (472220896) PubChem (472404311) PubChem (481155562) PubChem (483928230) PubChem (498155768) PubChem (505056125) PubChem (508534094) Thera-SAbDab YAbS

Avg A4D Score

-0.7049

Score Range

-0.72 to -0.69

Structures

Structure ID	Source PDB	Seq. Identity	Avg. A4D Score	pH (Min Agg.)	pH (Max Agg.)	Score CDR	Score non-CDR
A4DAB276_8blq_E_C	8blq	100%	-0.6869	6.5	9.0	-0.3207	-0.7357
A4DAB276_5l6y_H_L	5l6y	100%	-0.7229	6.5	4.0	-0.3749	-0.7681

Tralokinumab

Avg. A4D Score per Structure

pH at Min / Max Aggregation Propensity

Associated Structural Profiles Level 2